Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

REMS For Individual Opioids Show FDA Flexibility, Keep Class Options Open

Executive Summary

As FDA works with stakeholders on a class-wide Risk Evaluation and Mitigation Strategy for long-acting and extended-release opioids, the REMS that have been approved for individual opioid products indicate agency flexibility in addressing risk management, according to Edgar Adams, executive director of epidemiology at Covance

You may also be interested in...



Endo Sees Regulatory Setting For Opana ER As "A Moving Target"

CEO says company in discussions about "complete response" letter with FDA and will "work through" FDA's safety-first focus.

Endo Sees Regulatory Setting For Opana ER As "A Moving Target"

The “complete response” letter for the crush-resistant formulation of Endo Pharmaceuticals’ chronic pain drug Opana ER (oxymorphone) is not surprising, given that FDA has yet to settle on a risk management approach for extended-release opioids.

Endo Sees Regulatory Setting For Opana ER As "A Moving Target"

The “complete response” letter for the crush-resistant formulation of Endo Pharmaceuticals’ chronic pain drug Opana ER (oxymorphone) is not surprising, given that FDA has yet to settle on a risk management approach for extended-release opioids.

Related Content

Topics

UsernamePublicRestriction

Register

SC142962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel